Scarica l'app Stockscreener
1.06
4.95%
0.05
Dopo l'orario di chiusura:
1.05
-0.01
-0.94%
Precedente Chiudi:
$1.01
Aprire:
$1.04
Volume 24 ore:
142.01K
Relative Volume:
0.33
Capitalizzazione di mercato:
$16.45M
Reddito:
-
Utile/perdita netta:
$-7.51M
Rapporto P/E:
-0.803
EPS:
-1.32
Flusso di cassa netto:
$-8.02M
1 W Prestazione:
+6.43%
1M Prestazione:
+0.00%
6M Prestazione:
-15.19%
1 anno Prestazione:
+11.58%
Intervallo 1D:
$1.02
$1.06
Intervallo di 1 settimana:
$0.9801
$1.1019
Portata 52W:
$0.6554
$2.115
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Nome
Hoth Therapeutics Inc
Settore
Industria
Telefono
(646)756-2997
Indirizzo
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Compare HOTH vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
1.06 | 15.67M | 0 | -7.51M | -8.02M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.05 | 123.82B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.28 | 81.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
816.95 | 52.00B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.36 | 44.14B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
352.23 | 40.83B | 4.98B | 69.60M | 525.67M | 0.5198 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2019-10-15 | Iniziato | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Borsa (HOTH) Ultime notizie
Hoth Therapeutics adds clinical site for skin toxicity trial - Investing.com India
Hoth Therapeutics accelerates HT-001 trial enrollment with new clinical site as patient demand increases - marketscreener.com
Cancer rash drug HT-001 draws so many patients Hoth adds Miami site - Stock Titan
Performance Recap: Will Lufax Holding Ltd Depositary Receipt benefit from geopolitical trendsJuly 2025 EndofMonth & Long Hold Capital Preservation Plans - baoquankhu1.vn
Aug Reactions: Whats the outlook for Hoth Therapeutics Incs sectorJuly 2025 PreEarnings & Low Risk High Win Rate Picks - baoquankhu1.vn
Will Hoth Therapeutics Inc. announce a stock splitCPI Data & Technical Pattern Recognition Alerts - mfd.ru
Is Hoth Therapeutics Inc. stock trending bullishJuly 2025 Spike Watch & Technical Pattern Recognition Alerts - mfd.ru
Hoth Therapeutics receives U.S. notice of allowance for novel exon-skipping therapy targeting allergic diseases - marketscreener.com
Hoth Therapeutics Receives U.S. Notice Of Allowance For Novel Exon-Skipping Therapy Targeting Allergic Diseases - TradingView
Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases - PR Newswire
Hoth’s obesity treatment outperforms semaglutide in preclinical study - Investing.com Australia
Why Hoth Therapeutics Inc. stock is a must watch in 2025Trade Volume Summary & Pattern Based Trade Signal System - mfd.ru
Hoth Therapeutics' GDNF Study Outperforms Semaglutide in Key Metrics - Intellectia AI
Hoth Therapeutics's GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial - Asianet Newsable
Hoth Therapeutics' GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial - Stocktwits
Hoth Therapeutics announces groundbreaking positive results: HT-VA GDNF surpasses Semaglutide in weight loss - marketscreener.com
Hoth Therapeutics' GDNF Therapy Shows Breakthrough Efficacy in Obesity Treatment - Intellectia AI
Hoth Therapeutics rises as early obesity‑drug data in mice shows promise - TradingView
Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model - PR Newswire
EXCLUSIVE: Small Biotech Hoth Therapeutics Claims Experimental Obesity Drug Topped Famed Wegovy In Preclinical Study - Benzinga
Market Trends: How does Esperion Therapeutics Inc. score in quality rankings2025 Key Highlights & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation - Eastern Progress
Travel Stocks: What is CROXs TAM Total Addressable MarketJuly 2025 Selloffs & Reliable Volume Spike Alerts - baoquankhu1.vn
Is Hoth Therapeutics Inc stock trending bullishTrade Volume Summary & Intraday High Probability Setup Alerts - baoquankhu1.vn
Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets - marketscreener.com
Hoth Therapeutics (HOTH) Price Target Increased by 11.11% to 5.10 - Nasdaq
Aug Final Week: Can KVACW outperform in the next rallyTrade Analysis Summary & AI Powered Market Trend Analysis - baoquankhu1.vn
Hoth Therapeutics stock rises after filing patents for cancer therapy skin toxicity treatments - Investing.com Nigeria
Risk Analysis: Can BSVN expand into new marketsMarket Activity Report & Verified Stock Trade Ideas - baoquankhu1.vn
Market Leaders: What are analysts price targets for HOVRWJuly 2025 Volume & Safe Capital Growth Stock Tips - baoquankhu1.vn
Pharma News: What are the risks of holding Aduro Clean Technologies IncMarket Weekly Review & AI Forecast Swing Trade Picks - baoquankhu1.vn
Bear Alert: Can National Energy Services Reunited Corp Equity Warrant keep up with sector leaders2025 Major Catalysts & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Hoth Therapeutics gains after winning China patent for HT-KIT cancer program - MSN
Hoth Therapeutics stock rises after positive interim trial results By Investing.com - Investing.com Australia
Hoth reports positive interim results for cancer skin therapy By Investing.com - Investing.com Nigeria
Hoth Therapeutics Early Cancer Trial Succeeds With 100% Patient Response, Cuts Disease Severity By Half - Benzinga
Hoth Therapeutics stock rises after positive interim trial results - Investing.com
Hoth reports positive interim results for cancer skin therapy - Investing.com
Cancer patients on EGFR drugs report less toxicity and itch with HT-001 - stocktitan.net
Hoth Therapeutics secures Chinese patent for cancer cell therapy By Investing.com - Investing.com Nigeria
Sell Signal: What’s the outlook for Hoth Therapeutics Inc.’s sector2025 Price Action Summary & Expert Verified Movement Alerts - baoquankhu1.vn
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Hoth Therapeutics stock rises after securing Chinese patent for cancer therapy By Investing.com - Investing.com Australia
Hoth Therapeutics stock rises after securing Chinese patent for cancer therapy - Investing.com Nigeria
Hoth Therapeutics secures Chinese patent for cancer cell therapy - Investing.com
Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position - PR Newswire
Aug Analyst Calls: Can Salarius Pharmaceuticals Inc continue delivering strong returnsJuly 2025 Patterns & High Conviction Investment Ideas - baoquankhu1.vn
Hoth Therapeutics Inc Azioni (HOTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.52%
1.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):